KORRO BIO, INC.
NASDAQ: KRRO (Korro Bio, Inc.)
Last update: 13 hours ago10.02
-1.78 (-15.08%)
| Previous Close | 11.80 |
| Volume | 762,905 |
| Price / Sales | 50.54 |
| Price / Book | 1.43 |
| 52 Weeks Range |
| Operating Margin (TTM) | -981.18% |
| Diluted EPS (TTM) | -9.42 |
| Total Debt/Equity (MRQ) | 32.52% |
| Current Ratio (MRQ) | 9.41 |
| Operating Cash Flow (TTM) | -62.63 M |
| Levered Free Cash Flow (TTM) | -61.34 M |
| Return on Assets (TTM) | -29.82% |
| Return on Equity (TTM) | -60.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Korro Bio, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -3.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | -1.25 |
|
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 6.18% |
| % Held by Institutions | 104.23% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Lynx1 Capital Management Lp | 30 Jun 2026 | 1,538,296 |
| Atlas Venture Life Science Advisors, Llc | 30 Jun 2026 | 962,884 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DOLAN OLIVER | - | 13.42 | -7,358 | -99,405 |
| FORMELA JEAN FRANCOIS | - | 13.85 | -48,690 | -675,103 |
| Aggregate Net Quantity | -56,048 | |||
| Aggregate Net Value ($) | -774,508 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 13.59 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FORMELA JEAN FRANCOIS | Director | 14 Sep 2026 | Automatic sell (-) | 38,490 | 13.88 | 534,241 |
| DOLAN OLIVER | Officer | 11 Sep 2026 | Automatic sell (-) | 5 | 13.81 | 69 |
| FORMELA JEAN FRANCOIS | Director | 11 Sep 2026 | Automatic sell (-) | 10,200 | 13.81 | 140,862 |
| DOLAN OLIVER | Officer | 09 Sep 2026 | Automatic sell (-) | 6 | 12.93 | 78 |
| DOLAN OLIVER | Officer | 08 Sep 2026 | Automatic sell (-) | 7,347 | 13.51 | 99,258 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |